Home » Stocks » GLPG

Galapagos NV (GLPG)

Stock Price: $111.28 USD -0.04 (-0.04%)
Updated Jan 26, 2021 4:00 PM EST - Market closed
After-hours: $111.00 -0.28 (-0.25%) Jan 26, 4:21 PM
Market Cap 7.24B
Revenue (ttm) 1.01B
Net Income (ttm) 168.37M
Shares Out 54.47M
EPS (ttm) -1.69
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 26
Last Price $111.28
Previous Close $111.32
Change ($) -0.04
Change (%) -0.04%
Day's Open 110.85
Day's Range 110.60 - 112.03
Day's Volume 223,616
52-Week Range 96.85 - 274.03

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Benzinga - 1 week ago

Gilead Sciences, Inc. (NASDAQ: GILD) and its R&D partner Galapagos ADR Representing Ord Shs (NASDAQ: GLPG) received an upgrade each from Morgan Stanley. The Gilead, Galapagos Analyst: Matthew ...

Other stocks mentioned: GILD
GlobeNewsWire - 2 weeks ago

Mechelen, Belgium; 11 January 2021; 22.01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) received a transparency notification from Gilead Sciences, Inc.

Other stocks mentioned: GILD
GlobeNewsWire - 2 weeks ago

Mechelen, Belgium; 6 January 2021, 15.30 CET – Galapagos NV (Euronext & NASDAQ: GLPG) will participate in the 39th Annual J.P. Morgan Healthcare Conference on January 11-14, 2021.

PRNewsWire - 3 weeks ago

MECHELEN, Belgium and KRAKOW, Poland, Jan. 4, 2021 /PRNewswire/ -- Galapagos NV [Euronext & NASDAQ: GLPG] and Selvita S.A. [WSE: SLV] announced today that the strategic transaction in which Se...

GlobeNewsWire - 3 weeks ago

Mechelen, Belgium and Krakow, Poland – 04 January 2021, 22.01 TIME CET – Galapagos NV (Euronext & NASDAQ: GLPG) and Selvita S.A. (WSE: SLV) announced today that the strategic transaction in wh...

Seeking Alpha - 3 weeks ago

Due to the FDA's rejection of Filgotinib's 200 mg dosage for commercialisation in the US. Galapagos' earnings potential has been hampered severely. Yet, the current net cash position exceeds t...

Newsfile Corp - 1 month ago

New York, New York--(Newsfile Corp. - December 26, 2020) - Pomerantz LLP is investigating claims on behalf of investors of Galapagos NV ("Galapagos" or the "Company") (NASDAQ: GLPG). Such inve...

GlobeNewsWire - 1 month ago

Mechelen, Belgium; 23 December 2020, 18.00 CET – Galapagos NV (Euronext & NASDAQ: GLPG) today announces that Onno van de Stolpe, CEO of Galapagos, has committed to make a personal €10 million ...

Newsfile Corp - 1 month ago

New York, New York--(Newsfile Corp. - December 16, 2020) - Pomerantz LLP is investigating claims on behalf of investors of Galapagos NV ("Galapagos" or the "Company") (NASDAQ: GLPG). Such inve...

Investors Business Daily - 1 month ago

Gilead Sciences cut its losses on a rheumatoid arthritis treatment in partnership with Galapagos, sending GLPG stock tumbling on Wednesday. Gilead stock also fell less than 1%.

Other stocks mentioned: GILD
Business Wire - 1 month ago

FOSTER CITY, Calif. & MECHELEN, Belgium--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Galapagos NV (Euronext & Nasdaq: GLPG) today announced that the companies have agreed to amen...

Other stocks mentioned: GILD
GlobeNewsWire - 1 month ago

-- Gilead will Not Advance Jyseleca for the Treatment of Rheumatoid Arthritis (RA) in the U.S. Following FDA Type A Meeting -- -- Galapagos to Assume Sole Responsibility in Europe for Jyseleca...

Other stocks mentioned: GILD
GlobeNewsWire - 1 month ago

NEW YORK, Dec. 12, 2020 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Galapagos NV (“Galapagos” or the “Company”) (NASDAQ: GLPG).   Such investors are adv...

The Motley Fool - 1 month ago

Naughty or nice, shareholders aren't getting anything on their wish lists from these stocks this year.

Other stocks mentioned: BLUE, SAGE
PRNewsWire - 1 month ago

NEW YORK, Dec. 10, 2020 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Galapagos NV ("Galapagos" or the "Company") (NASDAQ: GLPG). Such investors are advised t...

GlobeNewsWire - 1 month ago

Mechelen, Belgium; 4 December 2020, 22.01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) announces a share capital increase arising from subscription right exercises.

GlobeNewsWire - 1 month ago

Mechelen, Belgium; 1 December 2020, 22.01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) announces first dosing in the new MANGROVE Phase 2 trial with investigational CFTR inhibitor GLPG2737 in p...

GlobeNewsWire - 1 month ago

Mechelen, Belgium; 30 November 2020, 22.01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) announces positive topline results with its investigational GPR84 antagonist GLPG1205 in Proof-of-Concept...

GlobeNewsWire - 2 months ago

-Strengthening Selvita's position as one of the largest preclinical contract research organizations in Europe -

Seeking Alpha - 2 months ago

Galapagos NV (GLPG) CEO Onno van de Stolpe on Q3 2020 Results - Earnings Call Transcript

GlobeNewsWire - 2 months ago

Mechelen, Belgium and Warsaw, Poland, 5 November 2020, 22.15 CET – Galapagos NV (Euronext & NASDAQ: GLPG) and OncoArendi Therapeutics SA (WSE: OAT), announced that they have signed an exclusiv...

GlobeNewsWire - 2 months ago

Webcast presentation tomorrow, 06 November 2020, at 14.00 CET / 8 AM ET, www.glpg.com , +32 2 793 38 47 , code 8542327

Business Wire - 2 months ago

FOSTER CITY, Calif. & MECHELEN, Belgium--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Galapagos NV (Euronext & Nasdaq: GLPG) today announced that the application for a new indicat...

Other stocks mentioned: GILD
GlobeNewsWire - 2 months ago

Mechelen, Belgium; 27 October 2020, 16.15 CET – Galapagos NV (Euronext & NASDAQ: GLPG) unveils the Toledo target family as a series of salt-inducible kinase inhibitors . Toledo exhibits a dual...

Seeking Alpha - 3 months ago

Galapagos is now tied tightly to Gilead. The stock price is near at the 52-week low.

InvestorPlace - 3 months ago

It's a good time to separate the weak from the strong. The post 7 Unhealthy Biotech Stocks To Sell Before They Sicken Your Portfolio appeared first on InvestorPlace.

Other stocks mentioned: CBPO, HRTX, ILMN, IONS, RGNX, LGND
Seeking Alpha - 3 months ago

Galapagos Knee Osteoarthritis Data, And Other News: The Good, Bad And Ugly Of Biopharma

Benzinga - 3 months ago

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 15)

Other stocks mentioned: AMRN
GlobeNewsWire - 3 months ago

Mechelen, Belgium and Paris, France, 15 OCTOBER 2020, 22.01 CET; regulated information –Servier and Galapagos NV (Euronext & NASDAQ: GLPG) report that no signal of activity was observed in the...

Zacks Investment Research - 3 months ago

Gilead (GILD) and partner Galapagos report positive data on filgotinib for the indication of active ulcerative colitis.

Other stocks mentioned: GILD
Business Wire - 3 months ago

FOSTER CITY, Calif., & MECHELEN, Belgium--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Galapagos NV (Euronext & Nasdaq: GLPG) today presented late-breaking data demonstrating sust...

Other stocks mentioned: GILD
Zacks Investment Research - 3 months ago

Galapagos (GLPG) doses the first patient in an early-stage study on its Toledo compound GLPG3970 for treating psoriasis. The same is also being studied for ulcerative colitis and rheumatoid ar...

GlobeNewsWire - 3 months ago

Mechelen, Belgium; 29 September 2020, 22.01 CET – Galapagos NV (Euronext & NASDAQ: GLPG) announces dosing of a first patient in their psoriasis trial, one of three patient trials currently rec...

Zacks Investment Research - 3 months ago

Gilead (GILD) and partner Galapagos win approval for their rheumatoid arthritis (RA) drug in Europe.

Other stocks mentioned: GILD
Zacks Investment Research - 3 months ago

Galapagos (GLPG) and Gilead announce approval of Jyseleca in Europe as a treatment for rheumatoid arthritis patients.

Business Wire - 4 months ago

FOSTER CITY, Calif., & MECHELEN, Belgium--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Galapagos NV (Euronext & Nasdaq: GLPG) today announced that the European Commission (EC) has...

Other stocks mentioned: GILD
Zacks Investment Research - 4 months ago

Galapagos (GLPG) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.

GlobeNewsWire - 5 months ago

Featuring patient burden and clinical development in IPF

PRNewsWire - 5 months ago

NEW YORK, Aug. 19, 2020 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Galapagos NV ("Galapagos" or the "Company") (NASDAQ: GLPG).

The Motley Fool - 5 months ago

The FDA dealt the biotech and its big partner a huge setback.

24/7 Wall Street - 5 months ago

When it rains, it pours. BioMarin Pharma was not the only company to receive a Complete Response Letter (CRL) from the U.S.

Other stocks mentioned: GILD
Market Watch - 5 months ago

Gilead Sciences GILD, -0.13% investigational treatment for moderately to severely active rheumatoid arthritis won't be approved by the U.S.

Other stocks mentioned: GILD
GlobeNewsWire - 5 months ago

 Mechelen, Belgium; 19 August 2020, 01.25 CET; regulated information – Galapagos (Euronext & Nasdaq: GLPG) announces today that Gilead Sciences, Inc. (Nasdaq: GILD) received a complete respons...

Other stocks mentioned: GILD
GlobeNewsWire - 5 months ago

-- Companies to jointly validate novel drug targets -- -- Scipher eligible for upfront, opt-in and milestone payments -- -- Galapagos to progress selected targets into drug discovery -- ...

Seeking Alpha - 5 months ago

Galapagos NV's (GLPG) CEO Onno van de Stolpe on Q2 2020 Results - Earnings Call Transcript

GlobeNewsWire - 5 months ago

Webcast presentation tomorrow, 7 August 2020, at 14.00 CET / 8 AM ET, www.glpg.com , +32 2 404 0659, code 8997710

The Motley Fool - 6 months ago

Binary events could send shares of these stocks screaming higher, or lower, soon.

Other stocks mentioned: BMRN, GWPH
GlobeNewsWire - 6 months ago

-- Clinical Development Program of Filgotinib Demonstrated Durable Efficacy Balanced with a Consistent Safety Profile in Rheumatoid Arthritis Through 52 Weeks -- Foster City, Calif., and M...

Other stocks mentioned: GILD
Business Wire - 6 months ago

Clinical Development Program of Filgotinib Demonstrated Durable Efficacy Balanced with a Consistent Safety Profile in Rheumatoid Arthritis Through 52 Weeks

Other stocks mentioned: GILD
GuruFocus - 6 months ago

In light of Novavax Inc. (NASDAQ:NVAX) getting $1.6 billion in federal aid for its coronavirus vaccine candidate, investors might find opportunities in biotechnology stocks that have high fina...

Other stocks mentioned: ALXN, NVO, REGN, VRTX

About GLPG

Galapagos NV, a clinical-stage biotechnology company, discovers, develops, and commercializes various small molecule medicines. Its clinical stage programs include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, small bowel CD, fistulizing CD, Sjögren's syndrome, ankylosing spondylitis, psoriatic arthritis, cutaneous lupus erythematosus, lupus membranous nephropathy, and uveitis. The company's clinical stage programs also comprise GLPG1690... [Read more...]

Industry
Biotechnology
IPO Date
May 6, 2005
CEO
Onno van de Stolpe
Employees
1,407
Stock Exchange
NASDAQ
Ticker Symbol
GLPG
Full Company Profile

Financial Performance

Financial numbers in millions EUR.
Financial Statements

Analyst Forecasts

According to 10 analysts, the average rating for Galapagos stock is "Hold." The 12-month stock price forecast is 110.87, which is a decrease of -0.37% from the latest price.

Price Target
$110.87
(-0.37% downside)
Analyst Consensus: Hold